BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D'Haens G, Kelly O, Battat R, Silverberg MS, Laharie D, Louis E, Savarino E, Bodini G, Yarur A, Boland BS, Afif W, Li XJ, Hale M, Ho J, Kondragunta V, Huang B, Kuy C, Okada L, Hester KD, Bray KR, Mimms L, Jain A, Singh S, Collins A, Valasek MA, Sandborn WJ, Vermeire S, Dulai PS. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology 2020; 158: 515-526. e10. [PMID: 31711925 DOI: 10.1053/j.gastro.2019.10.034] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Corsi F, Sorrentino L, Albasini S, Colombo F, Cigognini M, Massari A, Morasso C, Mazzucchelli S, Piccotti F, Ardizzone S, Sampietro GM, Truffi M. Circulating Fibroblast Activation Protein as Potential Biomarker in Patients With Inflammatory Bowel Disease. Front Med (Lausanne) 2021;8:725726. [PMID: 34621763 DOI: 10.3389/fmed.2021.725726] [Reference Citation Analysis]
2 Kessel C, Lavric M, Weinhage T, Brueckner M, de Roock S, Däbritz J, Weber J, Vastert SJ, Foell D. Serum biomarkers confirming stable remission in inflammatory bowel disease. Sci Rep 2021;11:6690. [PMID: 33758351 DOI: 10.1038/s41598-021-86251-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
3 Wang H, Ye J, Liu R, Chen G, Zhao J, Huang L, Yang F, Li M, Zhang S, Jingxie, Xiong L, Chen H, Xu Y, Su M, Xie Y, Li S, Zheng F, Geng L, Xu W, Gong S. Clinical Significance of CD147 in Children with Inflammatory Bowel Disease. Biomed Res Int 2020;2020:7647181. [PMID: 33015178 DOI: 10.1155/2020/7647181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Iacucci M, Jeffery L, Acharjee A, Nardone OM, Zardo D, Smith SCL, Bazarova A, Cannatelli R, Shivaji UN, Williams J, Gkoutos G, Ghosh S. Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis-An Exploratory Study to Define Deep Remission. Inflamm Bowel Dis 2021:izab059. [PMID: 34019073 DOI: 10.1093/ibd/izab059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kantasiripitak W, Wang Z, Spriet I, Ferrante M, Dreesen E. Recent advancements in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases. Expert Rev Clin Pharmacol 2022. [PMID: 35034509 DOI: 10.1080/17512433.2021.2028619] [Reference Citation Analysis]
6 Cui G, Florholmen J, Goll R. Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis? Front Immunol 2022;13:881112. [PMID: 35663996 DOI: 10.3389/fimmu.2022.881112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Abreu MT, Quintero M, Damas OM, Kerman DH, Deshpande A, Okada L, Dervieux T, Jain A. S0778 The Serum-Based Endoscopic Healing Index Provides an Accurate Representation of Endoscopic Inflammation in Crohn’s Disease Regardless of Disease Location: Results From an Academic Inflammatory Bowel Disease Cohort. Am J Gastroenterol 2020;115:S397-8. [DOI: 10.14309/01.ajg.0000705160.43347.fc] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chen R, Li L, Chao K, Hong M, Cao Q, Ye L, Zhou G, Fang X, Guo H, Cao X, Ye X, Zeng Z, Chen M, Zhang S. Platelet-to-lymphocyte percentage ratio index: a simple non-invasive index to monitor the endoscopic activity in Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820979442. [PMID: 33425010 DOI: 10.1177/1756284820979442] [Reference Citation Analysis]
10 Brand EC, Elias SG, Minderhoud IM, van der Veen JJ, Baert FJ, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, Louis E, Pariente B, Pierik MJ, van der Woude CJ, D'Haens GRAM, Vermeire S, Oldenburg B; Dutch Initiative on Crohn and Colitis. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease. Clin Gastroenterol Hepatol. 2020;18:1704-1718. [PMID: 31881273 DOI: 10.1016/j.cgh.2019.12.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
11 Wright E. Non-invasive biomarkers as treatment targets: What do we all need to know? J Gastroenterol Hepatol 2021;36 Suppl 1:12-3. [PMID: 33817840 DOI: 10.1111/jgh.15449] [Reference Citation Analysis]
12 Battat R. Serum Monitoring of Recurrence in Post-Operative Crohn's Disease: Have We Arrived? J Crohns Colitis 2022:jjac077. [PMID: 35737583 DOI: 10.1093/ecco-jcc/jjac077] [Reference Citation Analysis]
13 Noor NM, Lee JC. The Endoscopic Healing Index in Crohn's Disease: A Serum Proteomic Biomarker for Monitoring Disease Activity. Inflamm Bowel Dis 2022:izac126. [PMID: 35704706 DOI: 10.1093/ibd/izac126] [Reference Citation Analysis]
14 Borren NZ, Ananthakrishnan AN. Precision medicine: how multiomics will shape the future of inflammatory bowel disease? Curr Opin Gastroenterol 2022;38:382-7. [PMID: 35762697 DOI: 10.1097/MOG.0000000000000847] [Reference Citation Analysis]
15 Mitselos IV, Fousekis FS, Lamouri C, Katsanos KH, Christodoulou DK. Current noninvasive modalities in Crohn's disease monitoring. Ann Gastroenterol 2021;34:770-80. [PMID: 34815642 DOI: 10.20524/aog.2021.0648] [Reference Citation Analysis]
16 Elhag DA, Kumar M, Saadaoui M, Akobeng AK, Al-mudahka F, Elawad M, Al Khodor S. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. IJMS 2022;23:6966. [DOI: 10.3390/ijms23136966] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Walshe M, Borowski K, Battat R, Hudesman D, Wolf DC, Okada L, Jain A, Silverberg MS. Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index. Crohn's & Colitis 360 2021;3:otab032. [DOI: 10.1093/crocol/otab032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang W, Kong HF, Gao XD, Dong Z, Lu Y, Huang JG, Li H, Yang YP. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma. World J Gastroenterol 2020; 26(35): 5287-5301 [PMID: 32994688 DOI: 10.3748/wjg.v26.i35.5287] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
19 Spencer EA, Dubinsky MC. Precision Medicine in Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am 2021;68:1171-90. [PMID: 34736583 DOI: 10.1016/j.pcl.2021.07.011] [Reference Citation Analysis]
20 Agrawal M, Ungaro RC, Colombel JF. New Blood Marker of Endoscopic Disease Activity-A Step Forward in Treating Crohn's Disease to Target? Gastroenterology 2020;158:463-5. [PMID: 31866244 DOI: 10.1053/j.gastro.2019.12.015] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Cui G, Fan Q, Li Z, Goll R, Florholmen J. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. EBioMedicine 2021;66:103329. [PMID: 33862588 DOI: 10.1016/j.ebiom.2021.103329] [Reference Citation Analysis]
22 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
23 Battat R, Sandborn WJ. Advances in the Comprehensive Management of Postoperative Crohn's Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00383-9. [PMID: 33819666 DOI: 10.1016/j.cgh.2021.03.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
24 Honig G, Larkin PB, Heller C, Hurtado-Lorenzo A. Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:S1-S16. [PMID: 34791292 DOI: 10.1093/ibd/izab230] [Reference Citation Analysis]
25 Cai W, Cagan A, He Z, Ananthakrishnan AN. A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases. Dig Dis Sci 2021;66:760-7. [PMID: 32436120 DOI: 10.1007/s10620-020-06329-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
26 Porter AC, Aubrecht J, Birch C, Braun J, Cuff C, Dasgupta S, Gale JD, Hinton R, Hoffmann SC, Honig G, Linggi B, Schito M, Casteele NV, Sauer JM. Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions. Inflamm Bowel Dis 2020;26:1498-508. [PMID: 32840322 DOI: 10.1093/ibd/izaa215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
27 Zhou G, Chen R, Jiang Y, Li L, Zheng J, Li C, Zhang S, Chen M. Development and validation of a non-invasive biomarker-based model to identify endoscopic recurrences of Crohn’s disease. Therap Adv Gastroenterol 2022;15:175628482210890. [DOI: 10.1177/17562848221089096] [Reference Citation Analysis]
28 Friedberg S, Rubin DT. Intestinal Cancer and Dysplasia in Crohn's Disease. Gastroenterol Clin North Am 2022;51:369-79. [PMID: 35595420 DOI: 10.1016/j.gtc.2021.12.011] [Reference Citation Analysis]
29 Dreesen E, Vermeire S. Reply. Clin Gastroenterol Hepatol 2020;18:2632-3. [PMID: 32200086 DOI: 10.1016/j.cgh.2020.03.016] [Reference Citation Analysis]
30 Raine T, Danese S. Breaking Through the Therapeutic Ceiling: What Will It Take? Gastroenterology 2022:S0016-5085(21)04080-4. [PMID: 34995533 DOI: 10.1053/j.gastro.2021.09.078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Honig G, Heller C, Hurtado-Lorenzo A. Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2020;26:1451-62. [PMID: 32812036 DOI: 10.1093/ibd/izaa210] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
32 Zoumboulakis D, Cirella KR, Gougeon PY, Lourenssen SR, Blennerhassett MG. MMP-9 Processing of Intestinal Smooth Muscle-derived GDNF is Required for Neurotrophic Action on Enteric Neurons. Neuroscience 2020;443:8-18. [PMID: 32682824 DOI: 10.1016/j.neuroscience.2020.07.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 de Almeida LGN, Thode H, Eslambolchi Y, Chopra S, Young D, Gill S, Devel L, Dufour A. Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology. Pharmacol Rev 2022;74:712-68. [PMID: 35738680 DOI: 10.1124/pharmrev.121.000349] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Yarur AJ, Deepak P, Vande Casteele N, Battat R, Jain A, Okada L, Osterman M, Regueiro M. Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases. Dig Dis Sci 2021;66:3563-9. [PMID: 33089483 DOI: 10.1007/s10620-020-06669-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Mezghiche I, Yahia-Cherbal H, Rogge L, Bianchi E. Novel approaches to develop biomarkers predicting treatment responses to TNF-blockers. Expert Rev Clin Immunol 2021;17:331-54. [PMID: 33622154 DOI: 10.1080/1744666X.2021.1894926] [Reference Citation Analysis]
36 State M, Negreanu L, Voiosu T, Voiosu A, Balanescu P, Mateescu RB. Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review. World J Gastroenterol 2021; 27(16): 1828-1840 [PMID: 33967560 DOI: 10.3748/wjg.v27.i16.1828] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
37 Holmer AK, Boland BS, Singh S, Neill J, Le H, Miralles A, Collins AE, Sandborn WJ, Dulai PS. A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. Inflamm Bowel Dis 2022:izac117. [PMID: 35704691 DOI: 10.1093/ibd/izac117] [Reference Citation Analysis]
38 Kalla R, Adams AT, Bergemalm D, Vatn S, Kennedy NA, Ricanek P, Lindstrom J, Ocklind A, Hjelm F, Ventham NT, Ho GT, Petren C, Repsilber D, Söderholm J, Pierik M, D'Amato M, Gomollón F, Olbjorn C, Jahnsen J, Vatn MH, Halfvarson J, Satsangi J. Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. J Crohns Colitis 2021;15:699-708. [PMID: 33201212 DOI: 10.1093/ecco-jcc/jjaa230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]